Why the study?
Does direct renin inhibition with CP80794 improve hemodynamics and peripheral blood flows compared to captopril in dogs with pacing-induced heart failure?
Does direct renin inhibition with CP80794 improve hemodynamics and peripheral blood flows compared to captopril in dogs with pacing-induced heart failure?
In a canine model of pacing-induced heart failure, direct renin inhibition with CP80794 produced similar systemic hemodynamic improvements as captopril but significantly greater increases in renal blood flow.
Answers are grounded in this paper and cite their sources.
May support renal hemodynamic advantages of direct renin inhibition in experimental HF; leaves open translation to clinical practice.
OBJECTIVE: To compare the effects of angiotensin converting enzyme inhibition (ACEI) (captopril 1 mg/kg i.v.) to direct renin inhibition (CP80794 3 mg/kg i.v.) on left ventricular and systemic hemodynamics and peripheral blood flows in advanced congestive heart failure (CHF). METHODS: Conscious chronically instrumented dogs (n = 14) were treated with captopril, 1 mg/kg, i.v., or CP80794, 3 mg/kg, i.v., before and after development of advanced CHF induced by 4-7 weeks of rapid ventricular pacing. After advanced CHF, comparisons between the inhibitors were made at equihypotensive doses. RESULTS: In advanced CHF, both agents caused comparable reductions in mean arterial pressure (MAP) (-22% from 79 +/- 4 mmHg) and comparable increases (P < 0.01) in cardiac output (CP80794, 1.4 +/- 0.3 to 1.8 +/- 0.1 l/min; captopril, 1.4 +/- 0.1 to 1.9 +/- 0.1 l/min). Neither agent had a significant effect on LV contractility. In contrast, CP80794 caused a greater (P < 0.05) increase in renal blood flow (66 +/- 6% from 64 +/- 5 ml/min) compared to captopril (33 +/- 4% from 66 +/- 7 ml/min). CONCLUSIONS: Renin inhibition with CP80794 and ACEI with captopril caused comparable hemodynamic effects in advanced CHF. However, CP80794 caused significantly greater increases in renal blood flow and suppressed renin activity to a greater degree than captopril.
No takes yet. Share an insight, caveat, or question.
Richard P. Shannon (1997) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: